Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

537.40 +55.93 (+11.62%)
Streaming Delayed Price Updated: 2:29 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
News headline image
United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Reasons Investors Watch United Therapeutics (UTHR)
Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop. This was partly due to its softer quarterly results... 
Via StockStory
Topics Stocks
News headline image
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About United Therapeutics? ↗
 
Via Benzinga
News headline image
Evaluating UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s legendary strategy ↗
With a strategy that emphasized steady earnings growth and a strong market position, Peter Lynch sought out long-term winners. We put UNITED THERAPEUTICS CORP (NASDAQ:UTHR) to the test against his... 
Via Chartmill
News headline image
2 Value Stocks on Our Watchlist and 1 to Ignore
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
From United Therapeutics Corporation
Via Business Wire
News headline image
Why United Therapeutics (UTHR) Stock Is Down Today
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations,... 
Via StockStory
News headline image
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About United Therapeutics? ↗
 
Via Benzinga
News headline image
Earnings Outlook For United Therapeutics ↗
 
Via Benzinga
News headline image
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations
Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was... 
Via StockStory
News headline image
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
News headline image
United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
Decoding 7 Analyst Evaluations For United Therapeutics ↗
 
Via Benzinga
News headline image
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?
United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%. 
Via StockStory
Topics Stocks
News headline image
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
From United Therapeutics Corporation
Via Business Wire
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Announces Successful World’s First UKidney Transplant
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.